RBC Capital Markets and RBC Foundation USA’s 8-year Legacy of Support for EB Research Partnership Surpasses $230,000 for Rare Disease Research

*RBC Foundation USA’s long-term commitment accelerates the path to a cure for Epidermolysis Bullosa*

NEW YORK, NY, September 1, 2020 - EB Research Partnership (EBRP) today announced a $35,000 gift from longtime supporter, RBC Foundation USA, extending our 8-year partnership, which has surpassed $230,000 in funding for life-saving Epidermolysis Bullosa (EB) research projects and therapies. Since RBC Capital Markets and RBC Foundation USA’s inaugural gifts in 2013, EBRP has funded 75 projects under their innovative Venture Philanthropy model, directly impacting the clinical landscape; the number of clinical trials in EB has increased by 15x, from 2 when they started to more than 30 today, including 4 Phase III clinical trials for the first time ever.

“At RBC, we believe that supporting youth is critical to helping our communities prosper. Every child deserves the chance to live a healthy life and reach their fullest potential. We are proud to support EB Research Partnership and the extraordinary work they are doing to treat and ultimately cure Epidermolysis Bullosa.” says Matthew Stopnik, Co-Head of U.S. Investment Banking at RBC Capital Markets and longtime supporter of EB Research Partnership.

RBC Foundation USA prioritizes grants in the areas of youth and health, both of which EB Research Partnership covers under their mission to discover treatments and cures for EB, a rare and life-threatening genetic disorder that affects children from birth. An estimated 500,000 individuals worldwide live with this devastating disease. They are called “Butterfly Children,” because their skin is as fragile as the wings of a butterfly, facing severe pain, disfigurement, and wounds - both external and internal - that may never heal. While there are no treatments or a cure for EB currently, EBRP is dedicated to changing that as rapidly as possible. With partners like RBC Capital Markets and RBC Foundation USA, that goal is within reach.

Michael Hund, MBA, CEO at EB Research Partnership says “We are extremely grateful for RBC Capital Markets and RBC Foundation USA’s dedication to our cause over the last 8 years. Their longstanding support has allowed us to put speed into advancing breakthroughs and healing for patients and families battling EB, in the process, pioneering an innovative model for all rare diseases.”

While EB is considered a rare disease, collectively rare diseases affect 10% of the global population. EBRP’s innovative model and portfolio of research, made possible by forward-thinking partners like RBC Capital Markets and RBC Foundation USA, has the potential to
accelerate the path to cures for not only EB, but also the 7,000 other rare diseases in existence across the globe.

**About EB Research Partnership:**
Founded in 2010 by a dedicated group of parents and Jill and Ed Vedder (Pearl Jam), EB Research Partnership (EBRP) is the largest global nonprofit dedicated to funding research aimed at treating and ultimately curing Epidermolysis Bullosa (EB), a group of devastating and life-threatening skin disorders that affect individuals from birth.

EBRP utilizes an innovative venture philanthropy business model. When making a grant to a research project, they retain the added upside of generating a recurring revenue stream if the therapy or product is commercially successful, then use the return on investment to fund additional EB research until a cure is found. To learn more, visit [www.ebresearch.org](http://www.ebresearch.org).

**About RBC Capital Markets:**
RBC Capital Markets is recognized by the most significant corporations, institutional investors, asset managers, private equity firms, and governments around the globe as an innovative, trusted partner with an in-depth expertise in capital markets, banking, and finance.

We are well-established in the largest, most mature capital markets across North America, Europe, and the Asia-Pacific region, which collectively encompass more than 75% of global investment banking activity each year.

**Press Contact:**
Stephanie Ishoo
Director of Communications, EB Research Partnership
[stephanie@ebresearch.org](mailto:stephanie@ebresearch.org)
646-844-1077